The Kelch Like ECH Associated Protein 1 pipeline drugs market research report outlays comprehensive information on the Kelch Like ECH Associated Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Kelch Like ECH Associated Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Oncology, Genito Urinary System, and Gastrointestinal which include the indications Parkinson’s Disease, Friedreich Ataxia, Unspecified Cancer, Solid Tumor, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Oral Mucositis, and Inflammatory Bowel Disease. It also reviews key players involved in Kelch Like ECH Associated Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Kelch Like ECH Associated Protein 1 pipeline targets constitutes close to 19 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 2, 2, 6, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Kelch Like ECH Associated Protein 1 overview
KEAP1 protein contains KELCH-1 like domains, as well as a BTB/POZ domain. Kelch-like ECH-associated protein 1 interacts with NF-E2-related factor 2 in a redox-sensitive manner and the dissociation of the proteins in the cytoplasm is followed by transportation of NF-E2-related factor 2 to the nucleus. This interaction results in the expression of the catalytic subunit of gamma-glutamylcysteine synthetase.
For a complete picture of Kelch Like ECH Associated Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
